Evidence map›Paper›PMID 40125925›Full record

ArticleRenal failure2025

Urinary Basigin/CD147 is a useful marker of acute T cell-mediated rejection in kidney transplant recipients.

Kenta Futamura, Makoto Tsujita, Tomoki Kosugi, Akihiro Ryuge, Manabu Okada, Takahisa Hiramitsu, Shunji Narumi, Asami Takeda, Yoshihiko Watarai, Kunio Morozumi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Kenta FutamuraDepartment of Kidney Disease Center, Transplant Nephrology and Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Makoto TsujitaDepartment of Kidney Disease Center, Transplant Nephrology and Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.ORCID 0000-0001-6927-6353
Tomoki KosugiDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Akihiro RyugeInternal Medicine, Ryuge Internal Medicine Kamiotai Clinic, Nagoya, Japan.
Manabu OkadaDepartment of Kidney Disease Center, Transplant Nephrology and Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.ORCID 0000-0002-8446-7841
Takahisa HiramitsuDepartment of Kidney Disease Center, Transplant Nephrology and Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Shunji NarumiDepartment of Kidney Disease Center, Transplant Nephrology and Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Asami TakedaDepartment of Kidney Disease Center, Transplant Nephrology and Surgery, Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya, Japan.
Yoshihiko WataraiDepartment of Nephrology, Masuko Memorial Hospital, Nagoya, Japan.
Kunio MorozumiDepartment of Nephrology, Masuko Memorial Hospital, Nagoya, Japan.
Shoichi MaruyamaDepartment of Nephrology, Nagoya University Graduate School of Medicine, Nagoya, Japan.ORCID 0000-0002-8858-632X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAcute T cell-mediated rejection (ATCMR) is a severe negative outcome of kidney transplantation; however, it currently has no reliable marker in Japan.

methodsThis cross-sectional study was conducted at the Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital from 2016 to 2018 to determine whether plasma or urinary Basigin/CD147 is an effective marker of ATCMR. Plasma and urinary samples were obtained when episode graft biopsies were performed.

resultsForty-six kidney transplant recipients received graft biopsies. Three of them missed plasma and urinary samples and three in ATCMR were on postrejection treatment. Graft biopsy results revealed ATCMR in 12 of them, calcineurin inhibitor nephrotoxicity (CIN) in nine, chronic active antibody-mediated rejection (CAAMR) in nine, BK nephropathy, recurrence IgA nephropathy, necrotic glomerulonephritis, and infection-related glomerulonephritis in one each, and other complications in six. The urinary Basigin/CD147 levels of patients in the ATCMR group [759.4 (490.0, 843.0)] pg/gCre were significantly higher than the levels of patients in the CAAMR [247.0 (157.1, 288.8)] and CIN groups [379.1 (264.7, 456.7)] pg/gCre (

conclusionUrinary Basigin/CD147 may be a potential marker for ATCMR in kidney transplant recipients. Further studies will be needed to clarify the effectiveness of Basigin/CD147.

Indexed as

BasiginGraft RejectionKidney TransplantationT-LymphocytesAdultAgedBiomarkersBiopsyCross-Sectional StudiesFemaleHumansJapanKidneyMaleMiddle AgedBasiginBiomarkersBSG protein, humanacute T cell-mediated rejectionBasigin/CD147kidney biopsykidney transplantation

Identifiers

PMID40125925
PMCPMC11934155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.